Project Grant R01MH143042
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Feinstein Institutes for Medical Research a Project Grant of $519,558 under the Mental Health Research Grants program (CFDA 93.242), effective June 15, 2025 through April 30, 2030. The research project focuses on identifying and validating cerebellar-cortical circuitry biomarkers as predictive indicators of antipsychotic treatment response in first-episode psychosis patients. The primary deliverables...
- Federal Grant Award Summary The Feinstein Institutes for Medical Research received a $1,659,568 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded June 2, 2025, with completion targeted for May 31, 2030. The award funds the ESPRITO EPINET project, which aims to expand a learning health system (LHS) framework for improving treatment outcomes in early first-episode psychosis (FEP) care. The project will enroll an...
- Federal Grant Award Summary The Feinstein Institutes for Medical Research received $845,163 in project grant funding from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242), awarded August 1, 2025, with completion targeted for May 31, 2030. The project, titled "Vital Signs for Psychosis: Personalized Longitudinal Markers of Psychosis Severity Using Automated Speech and Language Analysis," develops objective, low-cost clinical markers...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $843,322 under the Mental Health Research Grants program (CFDA 93.242) to the Research Foundation For Mental Hygiene, Inc., through its New York State Psychiatric Institute division, beginning March 5, 2026, with completion scheduled for November 30, 2030. This Project Grant supports longitudinal positron emission tomography (PET) imaging research investigating antipsychotic medication binding to the dopamine-3...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $778,548 to the Research Foundation For Mental Hygiene, Inc. (Nathan S Kline Institute Division) on September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242) to support a five-year research project examining sensory contributions to third visual pathway (TVP) dysfunction in schizophrenia. The project, extending through July 31, 2030, investigates the neural mechanisms underlying social...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $394,200 to the Research Foundation For Mental Hygiene, Inc. (through its New York State Psychiatric Institute division) under the Mental Health Research Grants program (CFDA 93.242) on August 1, 2025, for a five-year project period extending through July 31, 2030. This Project Grant funds a clinical research study examining the role of the anterior hippocampus in major depressive disorder (MDD) pathogenesis....
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Rochester a $423,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) on May 5, 2025, with a completion date of May 4, 2027. This award supports research investigating visual perception and predictive processing dysfunction in schizophrenia and related psychiatric disorders. The research employs high-density electroencephalography (EEG) and innovative visual...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded UCLA a $408,843 Project Grant under the Mental Health Research Grants program (CFDA 93.242) on April 25, 2026, with completion targeted for March 31, 2028. This award supports research investigating the mechanistic relationship between autonomic nervous system (ANS) dysfunction and disrupted brain network organization in patients with first-episode schizophrenia. The research will examine how physiological...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a Project Grant of $197,640 under the Mental Health Research Grants program (CFDA 93.242), effective September 1, 2025 through August 31, 2030. This award supports an early-career investigator's research into the functional consequences of schizophrenia-associated genetic variants in GRIA3, a gene encoding the GluA3 subunit of the AMPA receptor...
- The National Institute of Mental Health (NIMH) awarded the University of Rochester a $437,496 Project Grant under the Mental Health Research Grants program (CFDA 93.242) for a two-year period from April 1, 2026 through March 31, 2028. This research project investigates brain barrier and glymphatic clearance disruptions as biomarkers for schizophrenia spectrum disorders, with particular focus on mid- to late-life first-episode psychosis (FEP). The research will examine three interconnected...
The National Institute of Mental Health (NIMH) awarded The Feinstein Institutes for Medical Research a $795,165 Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective June 1, 2026, through March 31, 2031. This research project investigates microRNAs (miRNAs) contained in neural-derived extracellular vesicles (NDEs) isolated from plasma as potential diagnostic and treatment response biomarkers in first-episode schizophrenia (FES). The study addresses a critical gap in psychiatric care by developing clinically relevant biomarkers to improve schizophrenia diagnosis and accelerate treatment response assessment, which currently relies solely on psychiatric interviews without reliable biological indicators. The project employs a mechanistic clinical trial approach utilizing a first-episode schizophrenia population to minimize confounding effects from prolonged antipsychotic exposure. By measuring brain-enriched miRNAs within NDEs—isolated using brain-specific surface markers—the research provides a less invasive window into central nervous system processes compared to traditional blood-based miRNA studies. Expected deliverables include peer-reviewed publications, mechanistic insights into miRNA dysregulation in schizophrenia, and validated biomarker candidates that could advance evidence-based treatment strategies and clinical decision-making for individuals experiencing first-episode psychosis.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $795.2k | 5/27/26 |